Figure 1: Reduction in the amount of F. prausnitzii in Inflammatory Bowel Diseases (IBD) patients. Sokol et al. IBD 2009
Figure 2: F. prausnitzii proportions at time of surgery according to the endoscopic recurrence status at 6 months (Sokol & al. 2008)
Figure 3: F. prausnitzii level at Infliximab discontinuation in CD patients Vs Relapse free survival rate (Rajca et al. IBD 2014)
Figure 4: Correlation F. prausnitzii and number of years to intestinal resection or colectomy (Shapiro et al. Cell Host & Microbe 2020)


Faecalibacterium Prausnitzii IN INFLAMMATORY BOWEL DISEASES

Clinical Observational Data
  • Low levels of F. prausnitzii are a sign of illness: (1) The F. prausnitzii  concentration level is decreased in patients suffering from inflammatory bowel diseases (Figure 1). (2) A reduction in the intestinal concentration of F. prausnitzii is associated with a higher risk of the postoperative recurrence of Crohn’s disease. (3) Low F. prausnitzii  levels have also been associated with higher relapse risks.
  • Good levels of F. prausnitzii are a sign of wellness. (1) For Crohn’s disease patients in remission, a high level of F. prausnitzii  is associated with remission maintenance, while a low level is associated with a higher risk of clinical flare-ups (Figure 2). (2) A high level of F. prausnitzii  is associated with a better response to current treatments (Figure 3). (3) A high level of F. prausnitzii  is associated with a lower need for surgery (Figure 4). (4) A high abundance of F. prausnitzii  has never been associated with any infections or any other disease in humans.
Learn more about how EXL01 is being used in Crohn’s disease
Learn more about F. prau


F. prau in cancer immunotherapy



Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.